FDA Approves Lilly's Foundayo Oral Weight-Loss Pill
Foundayo (orforglipron) was approved April 1 as the second daily oral GLP-1 for obesity, with trials showing about 11–12% weight loss at top doses and expedited review taking 50 to 100 days.
Overview
The FDA approved Foundayo (orforglipron) on April 1 as a once-daily oral GLP-1 medication to treat obesity, the agency said.
Foundayo is the second oral GLP-1 pill after the Wegovy pill was approved in December 2025, and the FDA granted expedited review under a new priority program that took roughly 50 to 100 days.
Novo Nordisk said comparisons claiming orforglipron is more effective than the Wegovy pill are "inaccurate and misleading," company officials said.
Lilly's trials reviewed by the FDA showed roughly 11% to 12.4% average weight loss at top doses (about 25 to 27 pounds) versus roughly 0.9% to 2.1% for placebo, the data showed.
Lilly said insured patients might pay as little as $25 per month with a savings card, cash prices could range $149 to $349 per month, and Medicare beneficiaries may pay $50 starting in July, the company said.
Analysis
Center-leaning sources present the approval mainly as factual reporting without partisan spin, emphasizing trial results, pricing, comparisons to existing GLP-1 drugs and noted side effects. Sources cite clinical data and regulatory context, use measured language (eg, 'expedited approval') and include benefits and risks, producing a neutral, information-focused account.